Table 1.
Patient demographics
| Patient characteristic | HER2 mutant (n=125) | HER3 mutant (n=16) | Total (n=141) |
|---|---|---|---|
| Age | |||
| Median (range), years | 61 (30–83) | 66 (39–82) | 61 (30–83) |
| <65 years, n (%) | 81 (64.8) | 7 (43.8) | 88 (62.4) |
| ≥65 years, n (%) | 44 (35.2) | 9 (56.3) | 53 (37.6) |
| Sex, n (%) | |||
| Female | 80 (64.0) | 12 (75.0) | 92 (65.2) |
| Male | 45 (36.0) | 4 (25.0) | 49 (34.8) |
| ECOG performance status, n (%) | |||
| 0 | 37 (29.6) | 1 (6.3) | 38 (27.0) |
| 1 | 83 (66.4) | 12 (75.0) | 95 (67.4) |
| 2 | 5 (4.0) | 3 (18.8) | 8 (5.7) |
| Prior systemic treatment lines, n (%) | |||
| Any | 121 (96.8) | 16 (100) | 137 (97.2) |
| 1 | 33 (26.4) | 1 (6.3) | 34 (24.1) |
| 2 | 30 (24.0) | 11 (68.8) | 41 (29.1) |
| ≥3 | 58 (46.4) | 4 (25.0) | 62 (44.0) |
| Median time from metastasis to enrolment, years (range) | 1.02 (0.0–15.0) | 1.13 (0.3–4.5) | 1.03 (0.0–15.0) |
| Tumour type, n (%) | |||
| Lung | 26 (20.8) | 0 (0) | 26 (18.4) |
| Breast | 25 (20.0) | 0 (0) | 25 (17.7) |
| Bladder | 16 (12.8) | 2 (12.5) | 18 (12.8) |
| Colorectal | 12 (9.6) | 5 (31.3) | 17 (12.1) |
| Biliary tract | 9 (7.2) | 2 (12.5) | 11 (7.8) |
| Endometrial | 7 (5.6) | 1 (6.3) | 8 (5.7) |
| Cervical | 5 (4.0) | 0 (0) | 5 (3.5) |
| Gastroesophageal | 5 (4.0) | 2 (12.5) | 7 (5.0) |
| Ovarian | 4 (3.2) | 1 (6.3) | 5 (3.5) |
| Other | 16 (12.8) | 3 (18.8) | 19 (13.5) |
ECOG, Eastern Cooperative Oncology Group.